不同GLP-1受体激素和急性胰腺炎之间的关联:病例系列和现实世界药监分析
Hui Guo1, Qian Guo2, Zhiqiang Li3
1Department of Pharmacy, Shanxi Cardiovascular Disease Hospital, Taiyuan, Shanxi, China.
所有葡萄糖类-1受体激动剂 (GLP-1RA) 都显示出急性胰腺炎 (AP) 的风险信号. 医疗保健提供者应监测患者是否有与GLP-1RA相关的这种严重不良事件.
科学领域:
- 药物监督 药物监督 药物监督
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
背景情况:
- 类似葡萄糖类-1受体激动剂 (GLP-1RA) 广泛用于血糖控制.
- 不同GLP-1RA之间急性胰腺炎 (AP) 的比较风险的现实数据有限.
研究的目的:
- 评估与各种GLP-1受体激活剂 (GLP-1RA) 相关的急性胰腺炎 (AP) 的风险.
- 用公共不良事件数据库和病例报告分析不同GLP-1RA中的AP信号.
主要方法:
- 描述了39名患者的病例系列,这些患者在接受GLP-1RA时经历了AP.
- 从2005年1月到2023年9月进行了FDA不良事件报告系统 (FAERS) 的数据挖掘.
- 使用不相称性分析 (ROR,PRR,BCPNN,MGPS) 来检测与GLP-1RA相关的AP信号.
主要成果:
- 总共有6,751个与GLP-1RA相关的AP个案安全报告 (ICSR) 从FAERS.获取.
- 在所有评估的GLP-1RA中检测到AP信号,特别强调exenatide和liraglutide.
- 大多数报告的AP病例 (98.3%) 是严重的,患者的中位数年龄为57岁.
结论:
- 在所有GLP-1受体激动剂中存在急性胰腺炎的显著报告信号.
- 医疗保健提供者必须对使用GLP-1RA的患者保持警,AP是一种可能危及生命的不良事件.
更多相关视频
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
07:10Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Acute Pancreatitis II: Clinical Manifestations and Management
Oral Hypoglycemic Agents: Glinides
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
